drugset

drugset / Trial / NCT00060515

RG2133 (2',3',5'-Tri-O-Acetyluridine) in Mitochondrial Disease

NCT00060515 ↗

Phase 1 Terminated 12 enrolled Repligen Corporation

Non-randomizedTreatment

Summary

The objective of the study is to determine the safety and tolerability of RG2133 in patients with Mitochondrial Disease.

Timeline

Start: —
Primary completion: —
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	2',3',5'-tri-O-acetyluridine	Unknown	—	—

Indications